Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine vs ropivacaine paravertebral block in bariatric surgery
ChiCTR2600120917Phase 4Not yet recruiting
- Sponsor
- Zhengzhou Central Hospital
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial in obesity comparing Group B (liposomal bupivacaine paravertebral block) with Group L (ropivacaine paravertebral block) (2 arms). Primary endpoint: QOR-15 score at 24 hours after surgery. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
liposomal bupivacaineropivacaine
03
Conditions
obesity
Beyond the preview
Go deeper on ChiCTR2600120917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120917.